5-[4-[[4-(trifluoromethyl)pyridin-3-yl]carbonylamino]phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-[4-[[4-(trifluoromethyl)pyridin-3-yl]carbonylamino]phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione
• 英文别名: N-[4-(2,4-dioxo-1H-benzo[g][1,5]benzodiazepin-5-yl)phenyl]-4-(trifluoromethyl)pyridine-3-carboxamide
• 化学式: C₂₆H₁₇F₃N₄O₃
• 分子量: 490.441
• InChiKey: MCVKLHWKBAERCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  91.4
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  特定基氨基甲酸脂酶 在 吡啶 、 platinum(IV) oxide 、 四(三苯基膦)钯 、 氢气 、 sodium hydride 、 碳酸氢钠 、 potassium carbonate 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 氯仿 、 甲苯 、 mineral oil 为溶剂， 反应 29.5h， 生成 5-[4-[[4-(trifluoromethyl)pyridin-3-yl]carbonylamino]phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione
  参考文献：
  名称：

  P2X4 RECEPTOR ANTAGONIST

  摘要：

  公开号：

  EP2803662B1

文献信息

• MEDICINE FOR DIABETIC PERIPHERAL NEUROPATHY
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP3848051A1

  公开（公告）日：2021-07-14

  The present invention relates to a medicine for preventing or treating pain in nociceptive pain, inflammatory pain, or neuropathic pain, the medicine comprising, as an active ingredient, a compound having a P2X4 receptor antagonist action, a tautomer of the compound, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof. The medicine has no effect on driving or machine operation ability, has no effect on car driving ability, does not require any restriction to administration thereof to a patient engaging in operation of a dangerous machine including driving a car, or can be administered to a patient engaging in operation of a dangerous machine including driving a car.

  本发明涉及一种用于预防或治疗痛觉疼痛、炎症性疼痛或神经病理性疼痛的药物，该药物作为活性成分包括具有P2X4受体拮抗剂作用的化合物、该化合物的同系物、其立体异构体、其药学上可接受的盐、其水合物或其溶液。该药物对驾驶或机器操作能力无影响，对汽车驾驶能力无影响，对从事危险机器操作（包括驾驶汽车）的患者用药无任何限制，或可对从事危险机器操作（包括驾驶汽车）的患者用药。
• P2X4 receptor antagonist
  申请人：NIPPON CHEMIPHAR CO., LTD

  公开号：US10633349B2

  公开（公告）日：2020-04-28

  The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R1 and R2 represent hydrogen atom and the like, or R1 and R2 bind together to form a naphthalene ring and the like together with the benzene ring to which they bind, R3 and R4 represent hydrogen atom and the like, R5 represents hydrogen atom and the like, R6 and R7 represent hydrogen atom and the like, X represents C, CH or N, Y represents N, NH or C(═O), provided that when X is N, Y is not N or NH, and when X is C or CH, Y is not C(═O), Z represents oxygen atom or sulfur atom, A represents benzene ring and the like, B represents NHC(═O) and the like, D represents an atomic bond and the like, E represents an atomic bond and the like, G represents benzene which may be substituted and the like, and m represents an integer of 0 to 5) or a pharmacologically acceptable salt thereof, and a P2X4 receptor antagonist.

  本发明涉及一种由以下通式(I)代表的二氮卓衍生物(式中，R1和R2代表氢原子等，或R1和R2结合在一起与它们结合的苯环一起形成萘环等，R3和R4代表氢原子等，R5代表氢原子等，R6和R7代表氢原子等，X代表C、CH或N，Y代表N、NH或C(═O)、Z 代表氧原子或硫原子，A 代表苯环等，B 代表 NHC(═O) 等，D 代表原子键等、或其药理学上可接受的盐，以及 P2X4 受体拮抗剂。
• MEDICAMENT FOR TREATMENT OF MULTIPLE SCLEROSIS
  申请人：NIPPON CHEMIPHAR CO., LTD.

  公开号：US20210121478A1

  公开（公告）日：2021-04-29

  A medicament for preventive and/or therapeutic treatment of multiple sclerosis, especially a pain accompanying multiple sclerosis such as neuropathic pain, which contains a compound having a P2X4 receptor antagonist activity such as a compound represented by the general formula (IH), or a salt thereof, or a hydrate or solvate thereof as an active ingredient.
• US9382236B2
  申请人：——

  公开号：US9382236B2

  公开（公告）日：2016-07-05
• P2X4 RECEPTOR ANTAGONIST
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP2803662B1

  公开（公告）日：2017-03-01